Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
about
Biology of Pseudomonas stutzeriMaintaining fluoroquinolone class efficacy: review of influencing factors.Selection of cross-resistance following exposure of Pseudomonas aeruginosa clinical isolates to ciprofloxacin or cefepime.BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.Staphylococcus aureus mutants selected by BMS-284756.parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.Bactericidal activities of BMS-284756, a novel Des-F(6)-quinolone, against Staphylococcus aureus strains with topoisomerase mutations.Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and beta-lactams against gram-positive clinical isolates.Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistanceAntimicrobial activities of garenoxacin (BMS 284756) against Asia-Pacific region clinical isolates from the SENTRY program, 1999 to 2001.In vitro activities of garenoxacin and levofloxacin against Chlamydia pneumoniae are not affected by presence of Mycoplasma DNA.Dual targeting of DNA gyrase and topoisomerase IV: target interactions of garenoxacin (BMS-284756, T-3811ME), a new desfluoroquinolone.In vitro activities of newer quinolones against bacteroides group organisms.Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis.Garenoxacin (BMS-284756) and moxifloxacin in experimental meningitis caused by vancomycin-tolerant pneumococci.In vitro susceptibilities to and bactericidal activities of garenoxacin (BMS-284756) and other antimicrobial agents against human mycoplasmas and ureaplasmasEfficacy of garenoxacin in treatment of experimental endocarditis due to Staphylococcus aureus or viridans group streptococciNovel agents for the treatment of resistant Gram-positive infections.Novel antibacterial agents for the treatment of serious Gram-positive infections.Multiple-dose safety and pharmacokinetics of oral garenoxacin in healthy subjects.Commercial broth microdilution panel validation and reproducibility trials for garenoxacin (BMS-284756), a novel desfluoroquinolone.Optimal dose finding of garenoxacin based on population pharmacokinetics/pharmacodynamics and Monte Carlo simulationA prescription event monitoring study on the utility of garenoxacin, a newer fluoroquinolone in India.Gemifloxacin: a new fluoroquinolone approved for treatment of respiratory infections.Moxifloxacin in the treatment of skin and skin structure infections.Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections.New quinolone antibiotics: a survey of the literature from 2005 to 2010.Inhibitory activities of quinolones against DNA gyrase of Chlamydia pneumoniae.In vitro activities of BMS-284756 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae.Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.Antipneumococcal activity of BMS 284756 compared to those of six other agents.Single-dose pharmacokinetics and penetration of BMS 284756 into an inflammatory exudate.In vitro activities of novel nonfluorinated quinolones PGE 9262932 and PGE 9509924 against clinical isolates of Staphylococcus aureus and Streptococcus pneumoniae with defined mutations in DNA gyrase and topoisomerase IV.In vitro activities of garenoxacin (BMS-284756) against 170 clinical isolates of nine Pasteurella species.In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates.Postantibiotic effects of garenoxacin (BMS-284756) against 12 gram-positive or -negative organisms.Time-kill studies of the antianaerobe activity of garenoxacin compared with those of nine other agents.
P2860
Q24549253-579B660C-8238-4D55-93F5-CE5D1495CF93Q30310427-3583129F-6A3D-434E-A55F-15C149458D86Q33836617-DF1CC20C-4706-404B-8C14-27D2142B80E2Q33983338-F06C406A-5527-4F01-B64B-1A57A18E137CQ33983475-30517C2B-4C95-4970-83DC-FA94F78E4BAFQ34077147-55952FF2-23D2-4BCB-8A25-2BCE3E454D5AQ34104362-B96B7DC2-8216-4D2A-9574-22ED72EAF426Q34104548-74F8917B-A608-4864-9982-A30A93AD3BADQ34106284-25F83DE4-3A2F-48D1-8626-7F5D88618235Q34139244-815FE6B7-3DA6-4E32-B817-2902EA25F37AQ34141733-59B3DFC0-DC58-4322-B612-019DD9201F0AQ34142238-161FF509-BD13-4B3C-A6AB-61BFE9660D04Q34143059-6BC5492E-5339-4774-817E-62F7472D369DQ34230600-657098E6-FBA5-4BC9-BEAF-4E6F5239EE00Q34252861-9F1A5E02-F34A-4BE3-BB82-57358A1950D7Q34719869-5F34D246-5034-4701-9FBD-AF41C5885E76Q34722677-2C9A3F8C-C01F-4E99-BF70-A7E781357966Q35005511-9F5EC663-1F85-4664-8B1A-CC02B0B66964Q35056042-FB1EF44C-39FA-4073-ABC9-36CEE22A33F1Q35073345-6B42FB5F-D0CD-49B7-8458-5494E29318F8Q35102747-ADD73AEE-B476-47D0-B062-78CF804DDE4CQ35636510-085EAE1F-2C14-457E-8AF2-D8E5B583C15FQ35644095-D03FF45A-5CFA-4F3E-8567-A1C5815EE9E4Q35686847-594330CE-9655-4EBE-A39C-B03C46F415EDQ35798789-8C670D2B-29DF-410B-BC82-E673ED9DCE79Q35919259-A56CDC53-51AE-41C3-A528-B3D0F8B50D46Q37625387-D2715ECB-4D79-401F-A9A1-1E7F9A5019D4Q37774376-4C2F9A0A-917C-414C-B3FD-2A52DA085AF6Q37869167-555AA41B-C9B4-4F2E-92C3-D399B7AC759DQ37872796-78E21834-63EE-4867-9276-AD98C4D897FFQ39478563-F57A3F50-4D9E-4740-B133-7CD4912A6FC7Q39479356-6A3BB6E6-B539-4C92-AFEC-2CF853E8C019Q39650891-EDA93095-7485-47C6-8A2A-9559ABAB7932Q39651041-A530C71C-F342-4956-9C04-576D09D8D70EQ39652121-F69822AA-6AB6-40EB-A92B-1003165994E6Q39652821-BD8CFA64-268C-4E33-927A-D4191F4B3E5AQ39652932-86B5345D-B720-47B5-B31F-0CA1E272EABEQ39731800-E0A3B46E-9AD5-4C55-8EC9-49C1E02A2FE4Q39731884-75C212E1-C132-4134-B2AC-46FB3976E1FAQ39743439-DBA97327-2BB1-47D6-9648-FF5281731E1E
P2860
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@ast
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@en
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@nl
type
label
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@ast
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@en
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@nl
prefLabel
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@ast
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@en
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@nl
P2093
P2860
P1476
Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756
@en
P2093
B Minassian
D P Bonner
E Gradelski
J C Fung-Tomc
L Aleksunes
P2860
P304
P356
10.1128/AAC.44.12.3351-3356.2000
P407
P577
2000-12-01T00:00:00Z